Grifols GIFLF
NASDAQ GIFLF
$11.08 +0.00 (+0.00%)
At close: Sep 8, 2026 · 4:00 PM EDT

Grifols (GIFLF) Receivables (2009 - 2025)

Grifols' (GIFLF) quarterly Receivables came in at $875.4 million in Q4 2025, up 4.62% on a YoY basis from $836.7 million in Q4 2024, and up 4.62% quarter-over-quarter from $836.7 million in Q4 2024.

Analysis

Grifols (GIFLF) Receivables (2009 - 2025) Analysis & Trends

Grifols (GIFLF) has reported Receivables for 17 consecutive years, with $875.4 million the latest figure, recorded in Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 4.62% year-over-year to $875.4 million; the trailing twelve-month figure through Dec 2025 stood at $875.4 million (up 4.62% YoY), and the FY2025 full-year result was $849.6 million, down 2.98% from the prior year.
  • Receivables improved to $875.4 million in Q4 2025 per GIFLF's latest filing, from $836.7 million in the prior quarter.
  • Across five years, Receivables topped out at $875.4 million in Q4 2025 and bottomed at $53.7 million in Q4 2023.
  • Historically, Receivables has averaged $604.3 million across 5 years, with a median of $696.1 million in 2022.
  • The sharpest annual moves came in 2023 and 2024: Receivables sank 92.28% in 2023, then jumped 1457.4% in 2024.
  • Over 5 years, Receivables stood at $559.6 million in 2021, then grew by 24.38% to $696.1 million in 2022, then tumbled by 92.28% to $53.7 million in 2023, then surged by 1457.4% to $836.7 million in 2024, then climbed by 4.62% to $875.4 million in 2025.
  • According to Business Quant data, Receivables over the past three periods registered $875.4 million, $836.7 million, and $53.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Amgen 203.97 Bn 189.99 Bn 7.24 Bn 10.23 Bn
2 Gilead Sciences 178.74 Bn 175.56 Bn 6.22 Bn 5.90 Bn
3 Vertex Pharmaceuticals 130.73 Bn 122.88 Bn 2.84 Bn 2.13 Bn
4 Regeneron Pharmaceuticals 80.42 Bn 72.42 Bn 3.93 Bn 6.57 Bn
5 Argenx Se 60.40 Bn 55.21 Bn 1.37 Bn 1.93 Bn
6 Moderna 57.65 Bn 52.52 Bn 52.00 Mn 160.00 Mn
7 Alnylam Pharmaceuticals 33.37 Bn 30.07 Bn 992.69 Mn 912.74 Mn
8 Biogen 32.15 Bn 30.86 Bn 1.96 Bn 1.89 Bn
9 Roivant Sciences 29.58 Bn 29.58 Bn 1.16 Mn -
10 Grifols 7.54 Bn 9.09 Bn 3.33 Bn 875.36 Mn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 875.36 Mn
Dec 31, 2024 836.71 Mn
Dec 31, 2023 53.72 Mn
Dec 31, 2022 696.08 Mn
Dec 31, 2021 559.63 Mn
Dec 31, 2020 543.20 Mn
Sep 30, 2020 663.81 Mn
Mar 31, 2020 560.38 Mn
Dec 31, 2019 500.65 Mn
Sep 30, 2019 516.62 Mn
Mar 31, 2019 678.24 Mn
Dec 31, 2018 412.71 Mn
Sep 30, 2018 538.34 Mn
Jun 30, 2018 464.64 Mn
Mar 31, 2018 496.64 Mn
Dec 31, 2017 384.88 Mn
Jun 30, 2017 429.83 Mn
Dec 31, 2016 492.31 Mn
Sep 30, 2016 482.23 Mn
Jun 30, 2016 561.65 Mn